Dolby Family Ventures

Dolby Family Ventures is a San Francisco-based venture capital firm founded in 2014 by David Dolby, investing in early-stage companies tackling frontier science and engineering challenges. Unaffiliated with Dolby Laboratories, the firm manages approximately $196 million in assets under management. The 16-person team is led by David Dolby as CEO, Senior Managing Director Pascal Levensohn, and Managing Director Andrew Krowne, supported by a distinguished Scientific Advisory Board. With 106 investments and a strong exit track record of 6 IPOs and 17 acquisitions, Dolby Family Ventures leads rounds across pre-seed, seed, and Series A with checks from $1 million to $25 million. The five core verticals are precision neuroscience (neurodegeneration, psychiatry, neurotech), life sciences platforms (regenerative medicine, computational biology), climate tech, aerospace, and digital deep tech. Portfolio companies include Motif Neurotech, Therini Bio, Ursa Major Technologies, Twelve, Paradromics, Bionaut Labs, and DigiLens. IPO exits include Athira Pharma, Eargo, Cognition Therapeutics, and Tempo Automation; acquisition exits include August (by Assa Abloy), Wickr (by Amazon), and Eyefluence (by Google). The firm takes a long-term collaborative approach, partnering with best-in-class innovators and syndicate partners to build transformative technology companies. Its willingness to back science-forward ventures at the earliest stages — often where commercial validation is years away — and the depth of the Scientific Advisory Board distinguish DFV from generalist firms operating across the same broad technology sectors.